Enveric Biosciences enters definitive agreement for an all-stock transaction to acquire MagicMed Industries Once closing is complete, Magic Med CEO Dr Joseph Tucker will be appointed chief executive officer of the enlarged company and David Johnson, chairman and CEO of Enveric will be appointed executive chairman The acquisition of MagicMed will expand and complement Enveric’s current pipeline of naturally occurring compounds, which is primarily focused on cannabinoids, to now include a robust portfolio of psychedelic-derived molecules Enveric Biosciences Inc. (NASDAQ:ENVB) said...